Bevacizumab in recurrent epithelial ovarian cancer: real-world experience from a tertiary cancer hospital in India
Bevacizumab plus chemotherapy followed by bevacizumab maintenance till disease progression significantly improved PFS in recurrent EOC. This real-world finding suggests a crucial insight into effective treatment options for financially compromised Indian populations with recurrent EOC.
Authors
- Ranajit Mandal (ORCID: https://orcid.org/0000-0003-0045-6270)
- Ranti Ghosh
- Suparna Mazumder (ORCID: https://orcid.org/0000-0002-9738-0040)
- Kushal Sen
- Debanjan Chakraborty (ORCID: https://orcid.org/0000-0002-4041-2451)
- Arup Kumar Bhattacharjee (ORCID: https://orcid.org/0000-0002-8374-1175)
- Tapas Kumar Maji (ORCID: https://orcid.org/0000-0002-7700-1146)
- Debarshi Lahiri (ORCID: https://orcid.org/0000-0002-6343-0361)
- Debjit Ghosh
- Jayanta Chakrabarti
Institutions
- Chittaranjan National Cancer Institute (IN)
Publication Details
- Journal
- ecancermedicalscience
- Published
- 2025-04-23
- DOI
- https://doi.org/10.3332/ecancer.2025.1897
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00